Recurrent respiratory papillomatosis: role of bevacizumab and HPV vaccination. A literature review with case presentations

1. Andrei EC, Baniţă IM, Munteanu MC, Busuioc CJ, Mateescu GO, Mălin RD, et al. Oral papillomatosis: its relation with human papilloma virus infection and local immunity - an update. Medicina (Kaunas) 2022; 58: 1103. doi: 10.3390/medicina58081103 Andrei EC Baniţă IM Munteanu MC Busuioc CJ Mateescu GO Mălin RD Oral papillomatosis: its relation with human papilloma virus infection and local immunity - an update . Medicina (Kaunas) 2022 ; 58 : 1103 . doi: 10.3390/medicina58081103 Open DOISearch in Google Scholar

2. Betz SJ. HPV-related papillary lesions of the oral mucosa: a review. Head Neck Pathol 2019; 13: 80-90. doi: 10.1007/s12105-019-01003-7 Betz SJ. HPV-related papillary lesions of the oral mucosa: a review . Head Neck Pathol 2019 ; 13 : 80 – 90 . doi: 10.1007/s12105-019-01003-7 Open DOISearch in Google Scholar

3. Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-54. doi: 10.1016/j.vaccine.2012.05.070 Gillison ML Alemany L Snijders PJF Chaturvedi A Steinberg BM Schwartz S Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis . Vaccine 2012 ; 30 ( Suppl 5 ): F34 – 54 . doi: 10.1016/j.vaccine.2012.05.070 Open DOISearch in Google Scholar

4. Syrjänen S. Human papillomavirus infections and oral tumors. Med Microbiol Immunol 2003; 192: 123-8. doi: 10.1007/s00430-002-0173-7 Syrjänen S. Human papillomavirus infections and oral tumors . Med Microbiol Immunol 2003 ; 192 : 123 – 8 . doi: 10.1007/s00430-002-0173-7 Open DOISearch in Google Scholar

5. Welschmeyer A, Berke G S. An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2021; 6: 226-33. doi: 10.1002/lio2.521 Welschmeyer A Berke G S. An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis . Laryngoscope Investig Otolaryngol 2021 ; 6 : 226 – 33 . doi: 10.1002/lio2.521 Open DOISearch in Google Scholar

6. Wang HFan, Wang SS, Tang YJ, Chen Y, Zheng M, Tang YL, et al. The double-edged sword-how human papillomaviruses interact with immu-nity in head and neck cancer. Front Immunol 2019; 10: 653. doi: 10.3389/fimmu.2019.00653 Wang HFan Wang SS Tang YJ Chen Y Zheng M Tang YL The double-edged sword-how human papillomaviruses interact with immu-nity in head and neck cancer . Front Immunol 2019 ; 10 : 653 . doi: 10.3389/fimmu.2019.00653 Open DOISearch in Google Scholar

7. Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses 2017; 9: 229. doi: 10.3390/v9080229 Shanmugasundaram S You J. Targeting persistent human papillomavirus infection . Viruses 2017 ; 9 : 229 . doi: 10.3390/v9080229 Open DOISearch in Google Scholar

8. Langer C, Wittekindt C, Wolf G. [Recurrent respiratory papillomatosis: current information on diagnosis and therapy]. [German]. Onkol up2date 2020; 2: 107-18. doi: 10.1055/a-1132-0051 Langer C Wittekindt C Wolf G. [Recurrent respiratory papillomatosis: current information on diagnosis and therapy]. [German] . Onkol up2date 2020 ; 2 : 107 – 18 . doi: 10.1055/a-1132-0051 Open DOISearch in Google Scholar

9. San Giorgi MRM, van den Heuvel ER, Tjon Pian Gi REA, Brunings JW, Chirila M, Friedrich G, et al. Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol 2016; 41: 448-53. doi: 10.1111/coa.12565 San Giorgi MRM van den Heuvel ER Tjon Pian Gi REA Brunings JW Chirila M Friedrich G Age of onset of recurrent respiratory papillomatosis: a distribution analysis . Clin Otolaryngol 2016 ; 41 : 448 – 53 . doi: 10.1111/coa.12565 Open DOISearch in Google Scholar

10. Evers G, Schliemann C, Beule A, Schmidt LH, Schulze AB, Kessler C, et al. Long-term follow-up on systemic bevacizumab treatment in recurrent res-piratory papillomatosis. Laryngoscope 2021; 131: E1926-E33. doi: 10.1002/lary.29351 Evers G Schliemann C Beule A Schmidt LH Schulze AB Kessler C Long-term follow-up on systemic bevacizumab treatment in recurrent res-piratory papillomatosis . Laryngoscope 2021 ; 131 : E1926 – E33 . doi: 10.1002/lary.29351 Open DOISearch in Google Scholar

11. Seedat RY. Juvenile-onset recurrent respiratory papillomatosis diagnosis and management – a developing country review. Pediatr Heal Med Ther 2020; 11: 39-46. doi: 10.2147/PHMT.S200186 Seedat RY. Juvenile-onset recurrent respiratory papillomatosis diagnosis and management – a developing country review . Pediatr Heal Med Ther 2020 ; 11 : 39 – 46 . doi: 10.2147/PHMT.S200186 Open DOISearch in Google Scholar

12. Ouda AM, Elsabagh AA, Elmakaty IM, Gupta I, Vranic S, Hamda Al-Thawadi H, et al. HPV and recurrent respiratory papillomatosis: a brief review. Life 2021; 11: 1-17. doi: 10.3390/life11111279 Ouda AM Elsabagh AA Elmakaty IM Gupta I Vranic S Hamda Al-Thawadi H HPV and recurrent respiratory papillomatosis: a brief review . Life 2021 ; 11 : 1 – 17 . doi: 10.3390/life11111279 Open DOISearch in Google Scholar

13. Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med 2017; 126: 116.21. doi: 10.1016/j.rmed.2017.03.030 Fortes HR von Ranke FM Escuissato DL Araujo Neto CA Zanetti G Hochhegger B Recurrent respiratory papillomatosis: a state-of-the-art review . Respir Med 2017 ; 126 : 116 21 . doi: 10.1016/j.rmed.2017.03.030 Open DOISearch in Google Scholar

14. Mauz P S, Zago M, Kurth R, Pawlita M, Holderried M, Thiericke J, et al. A case of recurrent respiratory papillomatosis with malignant transformation, HPV11 DNAemia, high L1 antibody titre and a fatal papillary endocardial lesion. Virol J 2014; 11: 1-6. doi: 10.1186/1743-422X-11-114 Mauz P S Zago M Kurth R Pawlita M Holderried M Thiericke J A case of recurrent respiratory papillomatosis with malignant transformation HPV11 DNAemia, high L1 antibody titre and a fatal papillary endocardial lesion . Virol J 2014 ; 11 : 1 – 6 . doi: 10.1186/1743-422X-11-114 Open DOISearch in Google Scholar

15. Bertino G, Pedretti F, Mauramati S, Filauro M, Vallin A, Mora F, et al. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study. Acta Otorhinolaryngol Ital 2023; 43: S111-S122. doi: 10.14639/0392-100X-suppl.1-43-2023-14 Bertino G Pedretti F Mauramati S Filauro M Vallin A Mora F Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study . Acta Otorhinolaryngol Ital 2023 ; 43 : S111 – S122 . doi: 10.14639/0392-100X-suppl.1-43-2023-14 Open DOISearch in Google Scholar

16. Torres-Canchala L, Cleves-Luna D, Arias-Valderrama O, Candelo E, Guerra MA, Pachajoa H, et al. Systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022. Child 2022; 10: 54. doi: 10.3390/children10010054 Torres-Canchala L Cleves-Luna D Arias-Valderrama O Candelo E Guerra MA Pachajoa H Systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022 . Child 2022 ; 10 : 54 . doi: 10.3390/children10010054 Open DOISearch in Google Scholar

17. Derkay CS, Wikner EE, Pransky S, Best SR, Zur K, Sidell DR, et al. Systemic use of bevacizumab for recurrent respiratory papillomatosis: who, what, where, when, and why? Laryngoscope 2023; 133: 2-3. doi: 10.1002/lary.30180 Derkay CS Wikner EE Pransky S Best SR Zur K Sidell DR Systemic use of bevacizumab for recurrent respiratory papillomatosis: who, what, where, when, and why? Laryngoscope 2023 ; 133 : 2 – 3 . doi: 10.1002/lary.30180 Open DOISearch in Google Scholar

18. Pogoda L, Ziylan F, Smeeing DPJ, Dikkers FG, Rinkel RNPM. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review. Eur Arch Otorhinolaryngol 2022; 279: 4229-40. doi: 10.1007/s00405-022-07388-6 Pogoda L Ziylan F Smeeing DPJ Dikkers FG Rinkel RNPM. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review . Eur Arch Otorhinolaryngol 2022 ; 279 : 4229 – 40 . doi: 10.1007/s00405-022-07388-6 Open DOISearch in Google Scholar

19. Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005; 114: 463-71. doi: 10.1177/000348940511400608 Gerein V Rastorguev E Gerein J Jecker P Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up . Ann Otol Rhinol Laryngol 2005 ; 114 : 463 – 71 . doi: 10.1177/000348940511400608 Open DOISearch in Google Scholar

20. Bergler WF, Götte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2000; 257: 263-9. doi: 10.1007/s004050050236 Bergler WF Götte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis . Eur Arch Otorhinolaryngol 2000 ; 257 : 263 – 9 . doi: 10.1007/s004050050236 Open DOISearch in Google Scholar

21. Patel A, Orban N. Infantile recurrent respiratory papillomatosis: review of adjuvant therapies. J Laryngol Otol 2021; 135: 958-63. doi: 10.1017/S0022215121002322 Patel A Orban N. Infantile recurrent respiratory papillomatosis: review of adjuvant therapies . J Laryngol Otol 2021 ; 135 : 958 – 63 . doi: 10.1017/S0022215121002322 Open DOISearch in Google Scholar

22. Tjon Pian GiREA, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W, et al. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®). Eur Arch Otorhinolaryngol 2012; 269: 361-2. doi: 10.1007/s00405-011-1804-7 Tjon Pian GiREA Dietz A Djukic V Eckel HE Friedrich G Golusinski W Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®) . Eur Arch Otorhinolaryngol 2012 ; 269 : 361 – 2 . doi: 10.1007/s00405-011-1804-7 Open DOISearch in Google Scholar

23. Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005; 114: 289-95. doi: 10.1177/000348940511400407 Rahbar R Vargas SO Folkman J McGill TJ Healy GB Tan X Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis . Ann Otol Rhinol Laryngol 2005 ; 114 : 289 – 95 . doi: 10.1177/000348940511400407 Open DOISearch in Google Scholar

24. Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 2014; 8: 1912-8 doi: 10.3892/ol.2014.2486 Mohr M Schliemann C Biermann C Schmidt LH Kessler T Schmidt J Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis . Oncol Lett 2014 ; 8 : 1912 – 8 doi: 10.3892/ol.2014.2486 Search in Google Scholar

25. Ryan MA, Leu GR, Upchurch PA, Tunkel DE, Walsh JM, Boss EF, et al. Systemic bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 2021; 131: 1138-46. doi: 10.1002/lary.29084 Ryan MA Leu GR Upchurch PA Tunkel DE Walsh JM Boss EF Systemic bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review . Laryngoscope 2021 ; 131 : 1138 – 46 . doi: 10.1002/lary.29084 Open DOISearch in Google Scholar

26. Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol 2011; 120: 627-34. doi: 10.1177/000348941112001001. Zeitels SM Barbu AM Landau-Zemer T Lopez-Guerra G Burns JA Friedman AD Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study . Ann Otol Rhinol Laryngol 2011 ; 120 : 627 – 34 . doi: 10.1177/000348941112001001 . Open DOISearch in Google Scholar

27. Zagzoog FH, Mogharbel AM, Alqutub A, Bukhari M, Almohizea MI. Intralesional cidofovir vs. bevacizumab for recurrent respiratory pap-illomatosis: a systematic review and indirect meta-analysis. Eur Arch Otorhinolaryngol 2024; 281: 601-27. doi: 10.1007/s00405-023-08279-0 Zagzoog FH Mogharbel AM Alqutub A Bukhari M Almohizea MI. Intralesional cidofovir vs. bevacizumab for recurrent respiratory pap-illomatosis: a systematic review and indirect meta-analysis . Eur Arch Otorhinolaryngol 2024 ; 281 : 601 – 27 . doi: 10.1007/s00405-023-08279-0 Open DOISearch in Google Scholar

28. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J. Voice 2015; 29: 223-9. doi: 10.1016/j. jvoice.2014.08.003 Young DL Moore MM Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma . J. Voice 2015 ; 29 : 223 – 9 . doi: 10.1016/j. jvoice.2014.08.003 Open DOISearch in Google Scholar

29. Mau T, Amin MR, Belafsky PC, Best SR, Friedman AD, Klein AM, et al. Interim results of a phase 1/2 open-label study of INO-3107 for HPV-6 and/or HPV-11-associated recurrent respiratory papillomatosis. Laryngoscope 2023; 133: 3087-93. doi: 10.1002/lary.30749 Mau T Amin MR Belafsky PC Best SR Friedman AD Klein AM Interim results of a phase 1/2 open-label study of INO-3107 for HPV-6 and/or HPV-11-associated recurrent respiratory papillomatosis . Laryngoscope 2023 ; 133 : 3087 – 93 . doi: 10.1002/lary.30749 Open DOISearch in Google Scholar

30. Nagel S, Busch C, Blankenburg T, Schütte W. [Treatment of respiratory papillomatosis − a case report on systemic treatment with bevacizumab]. [German]. Pneumologie 2009; 63: 387-9. doi: 10.1055/s-0029-1214714 Nagel S Busch C Blankenburg T Schütte W. [Treatment of respiratory papillomatosis − a case report on systemic treatment with bevacizumab]. [German] . Pneumologie 2009 ; 63 : 387 – 9 . doi: 10.1055/s-0029-1214714 Open DOISearch in Google Scholar

31. Best S R, Mohr M, Zur K. B. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope 2017; 127: 2225-9. doi: 10.1002/lary.26662 Best S R Mohr M Zur K. B. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey . Laryngoscope 2017 ; 127 : 2225 – 9 . doi: 10.1002/lary.26662 Open DOISearch in Google Scholar

32. Allen CT. Biologics for the treatment of recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012; 54: 769-77. doi: 10.1016/j.otc.2021.05.002 Allen CT. Biologics for the treatment of recurrent respiratory papillomatosis . Otolaryngol Clin North Am 2012 ; 54 : 769 – 77 . doi: 10.1016/j.otc.2021.05.002 Open DOISearch in Google Scholar

33. Yiu Y, Fayson S, Smith H, Matrka L. Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2019; 128: 309-15. doi: 10.1177/0003489418821695 Yiu Y Fayson S Smith H Matrka L. Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis . Ann Otol Rhinol Laryngol 2019 ; 128 : 309 – 15 . doi: 10.1177/0003489418821695 Open DOISearch in Google Scholar

34. Chirilǎ M, Bolboacǎ SD. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2014; 271: 1135-42. doi: 10.1007/s00405-013-2755-y Chirilǎ M Bolboacǎ SD. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis . Eur Arch Otorhinolaryngol 2014 ; 271 : 1135 – 42 . doi: 10.1007/s00405-013-2755-y Open DOISearch in Google Scholar